Skip to main
RMD
RMD logo

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 55%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is positioned for sustained growth, driven by a combination of increasing sleep apnea diagnoses, an aging population, and rising obesity rates, creating a structurally expanding market for respiratory care devices. The company has demonstrated its commitment to shareholders through consistent dividend increases and a strategic share repurchase program, indicating strong cash flow generation alongside planned investments in business operations, with revenue growth anticipated at a high-single-digit percentage rate for FY26. Additionally, ResMed's recent focus on digital health innovations aims to enhance patient care and optimize the out-of-hospital experience, potentially leading to enhanced market share and competitive advantages over time.

Bears say

ResMed is facing a negative outlook primarily due to concerns surrounding the potential medium-term disruption of Positive Airway Pressure (PAP) volumes stemming from the uptake of GLP-1 medications and expanded Obstructive Sleep Apnea (OSA) indications. While the company is currently outperforming the market, the risk associated with the adoption of these alternative treatments may adversely impact the future growth of its mask and device sales. Additionally, despite a structurally growing market driven by an increase in sleep apnea diagnoses, the competitive landscape may hinder ResMed's revenue prospects in the coming years.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 55% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $297.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $297.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.